LTR Pharma announced a development agreement with Strategic Drug Solutions, Inc. for development of a nasal spray for the treatment of esophageal motility disorders (difficulty in swallowing). The Australian company says that the product will be called Oroflow but did not provide any additional information. LTR is currently developing Spontan intranasal vardenafil for … [Read more...] about LTR Pharma announces agreement with SDS for development of nasal spray for difficulty in swallowing
Business
Ethris gets €10 million EU4Health grant for studies of ETH47 inhaled/nasal antiviral
Vaccine developer Ethris, which recently received $5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for development of spray-dried RNA vaccines for nasal delivery, has announced that EU4Health has awarded the company a €10 million grant to support research on ETH47, an mRNA-based antiviral designed specifically for respiratory … [Read more...] about Ethris gets €10 million EU4Health grant for studies of ETH47 inhaled/nasal antiviral
Akita gets Flu Lab grant for study of Profi nasal spray
Akita Biosciences announced that a grant from Flu Lab will fund a pilot study of the company's Profi prophylactic nasal spray in healthcare workers. Akita launched Profi, an OTC gel-forming drug-free nasal spray, in 2023 and currently sells the product online. The 8-week study will enroll workers in New York City public hospitals and clinics and will explore the … [Read more...] about Akita gets Flu Lab grant for study of Profi nasal spray
Rein Therapeutics gets 2 new US patents covering its LTI-03 DPI
Rein Therapeutics says that the US Patent and Trademark Office (USPTO) has recently granted US Patents No. 12,280,088 and No. 12,280,089, which cover the dry powder peptide formulation of the company's lead candidate, LTI-03. Both of the new patents are titled "Dry Powder Formulation of Caveolin-1 Peptides and Methods of Use Thereof." Earlier this year, Rein … [Read more...] about Rein Therapeutics gets 2 new US patents covering its LTI-03 DPI
AATec Medical raises €4 million for development of ATL-105 inhaled recombinant AAT
German biotech startup AATec Medical announced that it has raised €4 million prior to a series A financing, with the funds going to development of the company's ATL-105 inhaled recombinant alpha-1 antitrypsin (AAT) for the treatment of non-cystic fibrosis bronchiectasis (NCFB). The funding came from the German Federal Agency for Disruptive Innovation (SPRIND) as well … [Read more...] about AATec Medical raises €4 million for development of ATL-105 inhaled recombinant AAT
Lonza to develop spray dried formulations of Ethris’s nasal mRNA-based vaccines
Inhaled vaccine developer Ethris and CDMO Lonza have announced that Lonza will develop spray-dried formulations of Ethris mRNA-based vaccine candidates. Earlier this year, Ethris announced that it would receive $5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for development of spray-dried RNA vaccines for nasal delivery. The companies said … [Read more...] about Lonza to develop spray dried formulations of Ethris’s nasal mRNA-based vaccines
Chiesi announces plans for LGWP MDI production facility
Chiesi Group announced that it will spend €430 million to construct a new manufacturing facility on a site that it has acquired in Nerviano, Italy. The site will produce metered dose inhalers with low global warming potential (LGWP) propellants and will have development facilities for sterile biologics and dry powder inhalers. Plans for the 124,000 sq m site include … [Read more...] about Chiesi announces plans for LGWP MDI production facility
Paratek to acquire Optinose
US-based Paratek Pharmaceuticals will acquire all outstanding shares of intranasal drug developer Optinose in a deal worth up to $330 million, the companies said. According to the announcement, both companies' boards have approved the deal, which could close by mid-2025. Paratek will pay $9 per share up front plus up to an additional $5 per share in milestone payments … [Read more...] about Paratek to acquire Optinose
Cyrano licenses Resyca’s soft mist technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral loss of smell
Cyrano Therapeutics has acquired an exclusive license to use Resyca’s soft mist nasal spray technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral hyposmia. According to the announcement, the Phase 2 FLAVOR study of CYR-064 that was initiated in 2023 has been using an Ursatec spray pump enhanced with the Resyca technology for … [Read more...] about Cyrano licenses Resyca’s soft mist technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral loss of smell
Chance Pharma announces funding to support Phase 3 trial of CXG87 budesonide / formoterol DPI
DPI developer Chance Pharmaceuticals announced the completion of a financing round with participation from Heda Health Fund and Qihang Venture Capital, with proceeds intended to support Phase 3 trials of CXG87 inhaled dry powder budesonide / formoterol as well as development of some additional DPI formulations. The company did not specify the amount raised. Chance … [Read more...] about Chance Pharma announces funding to support Phase 3 trial of CXG87 budesonide / formoterol DPI